Free Trial
NASDAQ:ETNB

89bio Q3 2023 Earnings Report

89bio logo
$8.61 -0.12 (-1.37%)
Closing price 04:00 PM Eastern
Extended Trading
$8.60 -0.01 (-0.12%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

89bio EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

89bio Revenue Results

Actual Revenue
$1.00 million
Expected Revenue
$0.38 million
Beat/Miss
Beat by +$620.00 thousand
YoY Revenue Growth
N/A

89bio Announcement Details

Quarter
Q3 2023
Time
Q3 2023 Earnings Release
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

89bio's Q2 2025 earnings is scheduled for Thursday, May 8, 2025

89bio Earnings Headlines

Cantor Fitzgerald Upgrades 89bio (NASDAQ:ETNB) to Strong-Buy
Blackrock’s Sending THIS Crypto Higher on Purpose
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
ETNB Crosses Above Key Moving Average Level
See More 89bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email.

About 89bio

89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89bio Profile

More Earnings Resources from MarketBeat